The Pricing Evolution of Personalized Medicines

Grant D. Lawless, RPh, MD, FACP

Video Categories: Pricing

Grant Lawless discusses the changing landscape of pricing personalized medicines
June 16, 2015

The Biomarker: Melanoma

PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.

October 7, 2016

Tailoring Treatment Regimens for Patients with HR+/HER2-Negative Metastatic Breast Cancer

Dr Sunil Verma identifies how he makes treatment decisions for his patients, noting that he tends to use endocrine treatments instead of chemotherapy.